en · de · es · fr · pt
sr9009-notes.peptides6608.com › Topic › Background And Receptor Mechanism — What the Evidence Shows

Background And Receptor Mechanism — What the Evidence Shows

By Editorial Desk · published 2025-08-26 · last reviewed 2025-10-01 · Topic

This is a working overview of anti-doping testing, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-10-01. Anything still debated is marked as such rather than presented as settled.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Handling, Analysis, and Regulation

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Related pages on this site

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Notes from published material

=== June === 8 June – Police in Roraima rescue 108 Cuban migrants attempting to enter the country from Guyana and arrest five suspected human traffickers. 11 June–19 July – Brazil participates at the 2026 FIFA World Cup 13 June – A 21-year-old woman dies after two rope jumping instructors throw her from a bridge in Limeira without harnessing her to safety equipment. 14 June – Six people, including American musician Oliver Tree, are killed when two helicopters collide over Rio de Janeiro. 16 June – The Supreme Federal Court sentences Eduardo Bolsonaro to four years and two months' imprisonment for trying to involve the United States in the trial of his father, former president Jair Bolsonaro, over the 2022–2023 Brazilian coup plot. Twenty-five people, including 18 Venezuelan nationals, are arrested in Roraima as part of an operation against the Tren de Aragua.

=== Nerve supply === The lungs are supplied by nerves of the autonomic nervous system. Input from the parasympathetic nervous system occurs via the vagus nerve. When stimulated by acetylcholine, this causes constriction of the smooth muscle lining the bronchus and bronchioles, and increases the secretions from glands. The lungs also have a sympathetic tone from norepinephrine acting on the beta 2 adrenoceptors in the respiratory tract, which causes bronchodilation. The action of breathing takes place because of nerve signals sent by the respiratory center in the brainstem, along the phrenic nerve from the cervical plexus to the diaphragm.

In patients on a vitamin K antagonist such as warfarin with supratherapeutic INR but INR less than 10 and no bleeding, it is enough to lower the dose or omit a dose, monitor the INR and resume the vitamin K antagonist at an adjusted lower dose when the target INR is reached. For people who need rapid reversal of the vitamin K antagonist – such as due to serious bleeding – or who need emergency surgery, the effects of warfarin can be reversed with vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP).

Sources: en.wikipedia.org

Further detail

Long dsRNA (which can come from hairpin, complementary RNAs, and RNA-dependent RNA polymerases) is cleaved by an endo-ribonuclease called Dicer. Dicer cuts the long dsRNA to form short interfering RNA or siRNA; this is what enables the molecules to form the RNA-Induced Silencing Complex (RISC). Once siRNA enters the cell, it gets incorporated into other proteins to form the RISC. Once the siRNA is part of the RISC complex, the siRNA is unwound to form single-stranded siRNA. The strand that is thermodynamically less stable due to its base pairing at the 5' end is chosen to remain part of the RISC complex. The single-stranded siRNA, which is part of the RISC complex, can now scan and find a complementary mRNA. Once the single-stranded siRNA (part of the RISC complex) binds to its target mRNA, it induces mRNA cleavage. The mRNA is now cut and recognized as abnormal by the cell. This causes degradation of the mRNA and, in turn, no translation of the mRNA into amino acids and then proteins, thus silencing the gene that encodes that mRNA. siRNA is also similar to miRNA; however, miRNAs are derived from shorter stemloop RNA products. miRNAs typically silence genes by repression of translation and have broader specificity of action, while siRNAs typically work with higher specificity by cleaving the mRNA before translation, with 100% complementarity.

=== Cell turnover === Epithelia turn over at some of the fastest rates in the body. For epithelial layers to maintain constant cell numbers essential to their functions, the number of cells that divide must match those that die. They do this mechanically. If there are too few of the cells, the stretch that they experience rapidly activates cell division. Alternatively, when too many cells accumulate, crowding triggers their death by activation epithelial cell extrusion. Here, cells fated for elimination are seamlessly squeezed out by contracting a band of actin and myosin around and below the cell, preventing any gaps from forming that could disrupt their barriers. Failure to do so can result in aggressive tumors and their invasion by aberrant basal cell extrusion.

=== Laboratory synthesis === Heavy neutron irradiation of plutonium results in four major isotopes of einsteinium: 253Es (α-emitter; half-life 20.47 days, spontaneous fission half-life 7×105 years); 254mEs (β-emitter, half-life 39.3 hours), 254Es (α-emitter, half-life 276 days) and 255Es (β-emitter, half-life 39.8 days). An alternative route involves bombardment of uranium-238 with high-intensity nitrogen or oxygen ion beams. 247Es (half-life 4.55 min) was produced by irradiating 241Am with carbon or 238U with nitrogen ions. The latter reaction was first realized in 1967 in Dubna, Russia, and the involved scientists were awarded the Lenin Komsomol Prize. 248Es was produced by irradiating 249Cf with deuterium ions. It mainly β-decays to 248Cf with a half-life of 25±5 minutes, but also releases 6.87-MeV α-particles; the ratio of β's to α-particles is about 400.

Sources: en.wikipedia.org

Background from the literature

Because reporter genes such as lacZ, GFP, and luciferase are widely used in standardized plasmid constructs for gene expression studies, well-characterized reporter vectors are preserved as reference materials in public biological resource centres and non-profit repositories such as BCCM/GeneCorner and Addgene, supporting reproducibility in molecular biology research.

=== Composition and selectivity === Condensate components are usually divided into scaffolds, which drive phase separation, and clients, which do not phase separate on their own but can still be recruited into the dense phase. Client recruitment depends on the number of available binding sites as well as the valency and affinity of the client, so changes in scaffold stoichiometry can alter the composition of the condensate. Partitioning is also influenced by physical factors that are distinct from specific binding. Because condensates consist of dense networks of intrinsically disordered regions (IDRs), inserting a molecule restricts the conformational freedom of the surrounding chains, resulting in an entropic penalty that increases with particle size. Calculations combined with coarse-grained modelling show that the free energy of insertion increases with both IDR density and particle size, and becomes dependent on particle surface area once the particle is larger than the network mesh size. At typical IDR concentrations, particles as small as 4 nm in diameter can be almost entirely excluded, with approximately 97% exclusion in the absence of favourable interactions with condensate components.

Formylation refers to any chemical processes in which a compound is functionalized with a formyl group (-CH=O). In organic chemistry, the term is most commonly used with regard to aromatic compounds (for example, the conversion of benzene to benzaldehyde in the Gattermann–Koch reaction). In biochemistry, the reaction is catalysed by enzymes such as formyltransferases. Formylation generally involves the use of formylation agents, reagents that give rise to the CHO group. Among the many formylation reagents, particularly important are formic acid and carbon monoxide. A formylation reaction in organic chemistry refers to organic reactions in which an organic compound is functionalized with a formyl group (-CH=O). The reaction is a route to aldehydes (C-CH=O), formamides (N-CH=O), and formate esters (O-CH=O).

== Operation == The extraction cells consist of hollow bodies with inlets and outlets of liquid connection. The cells are first filled with the liquid chosen to be the stationary phase. Under rotation, the pumping of the mobile phase is started, which enters the cells from the inlet. When entering the flow of mobiles phase forms small droplets according to the Stokes' law, which is called atomization. These droplets fall through the stationary phase, creating a high interface area, which is called the extraction. At the end of the cells, these droplets unite due to the surface tension, which is called settling. When a sample mixture is injected as a plug into the flow of mobile phase the compounds of the mixtures elute according to their partition coefficients:

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Network